The Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) is valid for assessing the risk for skin cancer among solid organ transplant recipients (SOTRs), according to a study published online Nov. 23 in JAMA Dermatology.

Álvaro Gómez-Tomás, M.D., from Hospital Universitari Vall d'Hebron in Barcelona, Spain, and colleagues conducted a retrospective external validation study using data from European SOTRs from transplant centers in the Netherlands and Spain to validate the SUNTRAC tool. The discriminative ability of the SUNTRAC tool was examined and calibration was assessed by comparing projected skin cancer incidences.

"Having a tool that can quickly and correctly stratify SOTRs according to their relative skin cancer risk is a great aid for the clinician and a fundamental step in defining guidelines to ensure adequate screening and dermatological follow-up of these patients," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)